Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Blumberg Richard P. 2. Issuer Name and Ticker or Trading Symbol GUIDED THERAPEUTICS INC [GTHP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 5835 PEACHTREE CORNERS EAST, SUITE B 3. Date of Earliest Transaction (Month/Day/Year) 02/25-05:00/2026 (Street) PEACHTREE CORNERS, GA 30092 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/25-05:00/2026 M 1,000,000 A (1) 8,924,180 D Common Stock 03/26-05:00/2026 J(4) 56,093 A (4) 8,980,273 D Preferred Series F Stock 03/26-05:00/2026 J(5) 260 D (5) 0 D Common Stock 03/26-05:00/2026 J(5) 1,040,000 A (5) 10,020,273 D Common Stock 03/26-05:00/2026 J(6) 19,038 A (6) 10,039,311 D Preferred Series F-2 Stock 03/26-05:00/2026 J(7) 88 D (7) 0 D Common Stock 03/26-05:00/2026 J(7) 352,000 A (7) 10,391,311 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Warrants

$0.65

02/25-05:00/2026

D(1)

1,000,000

09/01/2022

09/01/2026

Common Stock

1,000,000

(1)

0

D

Warrants

$0.65

02/25-05:00/2026

A(1)

1,000,000

02/25/2026

09/01/2027

Common Stock

1,000,000

(1)

1,000,000

D

Warrants

$0.5

02/25-05:00/2026

D(1)

1,000,000

09/01/2022

09/01/2026

Common Stock

1,000,000

(1)

0

D

Warrants

$0.2

02/25-05:00/2026

A(1)

1,000,000

02/25/2026

02/25/2026

Common Stock

1,000,000

(1)

1,000,000

D

Warrants

$0.2

02/25-05:00/2026

M(1)

1,000,000

02/25/2026

02/25/2026

Common Stock

1,000,000

$0.2(1)

0

D

Warrants

$0.3

03/01-05:00/2026

H(2)

900,000

03/01/2023

03/01/2026

Common Stock

900,000

$0.3

2,700,000

D

Stock Options

$0.29

03/10-05:00/2026

A

110,000

(3)

03/09/2036

Common Stock

110,000

$ 0

110,000

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Blumberg Richard P. 5835 PEACHTREE CORNERS EAST SUITE B PEACHTREE CORNERS, GA 30092	X	X

Signatures

/s/ Richard P. Blumberg		05/05/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027.
(2)	900,000 warrants to purchase shares of common stock with an exercise price of $0.30, with an issuance date of March 1, 2023, expired on March 1, 2026, without being exercised.
(3)	One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029.
(4)	These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773.
(5)	On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price.
(6)	These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.2773.
(7)	On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.